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This article reports the current evidence and expert opinions on diagnosis and management of neuro-
genic lower urinary tract dysfunction (NLUTD) in Taiwan. The main problems of NLUTD are failure to
store, failure to empty, and combined failure to store and empty. The priority of management of NLUTD
should follow the order of: (1) preservation of renal function; (2) freedom from urinary tract infection
(UTI); (3) efﬁcient bladder emptying; and (4) freedom from indwelling catheter, and patients’ expecta-
tion of management should be respected. Management of the urinary tract in patients with spinal cord
injury (SCI) or multiple sclerosis (MS) must be based on urodynamic ﬁndings, rather than inferences
from the neurologic evaluation. Selecting high risk patients is important to prevent renal function
impairment in patients with chronic NLUTD. Patients with NLUTD should be regularly followed up for
their lower urinary tract dysfunction by urodynamic study and any urological complication should be
adequately treated. Avoiding a chronic indwelling catheter can reduce the incidence of developing a low
compliant bladder. Antimuscarinic agents with clean intermittent catheterization (CIC) may reduce
urological complications and improve quality of life (QoL) in patients with NLUTD. Intravesical injection
of botulinum toxin A provides an alternative treatment for refractory detrusor overactivity (DO) or low
compliant bladder and can replace the need for bladder augmentation. When surgical intervention is
necessary, we should consider the least invasive type of surgery and reversible procedure ﬁrst and avoid
any unnecessary surgery of the lower urinary tract. Keeping the bladder and urethra in a good condition
without interference of the neuromuscular continuity provides patients with NLUTD a chance for future
new technologies. It is most important to never give up on improving the QoL in patients with NLUTD.
Copyright  2014, Taiwan Urological Association. Published by Elsevier Taiwan LLC.
Open access under CC BY-NC-ND license.ddhist Tzu Chi General Hos-
aiwan.
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H.-C. Kuo et al. / Urological Science 25 (2014) 35e4136International Continence Society (ICS).1 [LE,1a,A] AD ¼ autonomic
dysreﬂexia; BND¼ bladder neck dysfunction; BOO¼ bladder outlet
obstruction; CVA ¼ cerebrovascular accidents; CIC ¼ clean inter-
mittent catheterization; DA ¼ detrusor areﬂexia; DHIC ¼ detrusor
hyperreﬂexia with impaired detrusor contractility; DO ¼ detrusor
overactivity; DSD ¼ detrusor sphincter dyssynergia; DU ¼ detrusor
underactivity; GFR ¼ glomerular ﬁltration rate; HR-QoL ¼ health-
related Quality of Life; LUTS ¼ lower urinary tract symptoms;
Qmax ¼ maximum ﬂow rate; MS ¼ multiple sclerosis;
NDO ¼ neurogenic detrusor overactivity; NLUTD ¼ neurogenic
lower urinary tract dysfunction; NVD ¼ neurogenic voiding
dysfunction; PD ¼ Parkinson’s disease; PVR ¼ post-void residual;
SCI ¼ spinal cord injury; UTI ¼ urinary tract infection;
UUI ¼ urgency urinary incontinence; and VUR ¼ vesicoureteral
reﬂux.
1. Introduction
NLUTD includes the dysfunction of urinary bladder and urethra
due to central nervous system or peripheral neurogenic lesions.
CVA, intracranial lesion, PD, cerebral palsy, MS, transverse myelitis,
spinal cord lesions, and diabetic neuropathy, etc., will result in
NLUTD.2 [LE, 2a,B]
NLUTD presents a great disease burden on patients, affecting not
only their prognosis, but also QoL, self-esteem, and families’ rela-
tionship. It is commonly associated with urinary incontinence,
voiding difﬁculty, reduction in bladder compliance, upper urinary
tract damage, and UTI.3 [LE, 2a,B]
The priority of management of NLUTD should include: (1)
preservation of renal function; (2) freedom from UTIs; (3) efﬁcient
bladder emptying; and (4) freedom from indwelling catheter and
patients’ expectation should be respected.4 [LE, 3b,C]
2. Purpose
The purpose of these clinical guidelines is to provide informa-
tion on the incidence, deﬁnitions, diagnosis, therapy, and follow up
observation of the condition of NLUTD. Among all types of NLUTD,
SCI and MS remain the most difﬁcult disorders to manage. These
guidelines may be useful for physicians and patients in the man-
agement of NLUTD, especially SCI and MS.
3. Etiology of NLUTD
NLUTD may be caused by various diseases and events affecting
the nervous systems controlling the lower urinary tract. NLUTD
should be considered in patients with neurological lesions and
LUTS, such as acute urinary retention or UUI. The etiology of NLUTD
includes peripheral neuropathy, diabetes,5 [LE, 2a,A] iatrogenic,6
[LE, 4,C] demyelinization,7 [LE, 2a,B] dementia,8 [LE, 2a,B] basal
ganglia pathology,9 [LE, 4,C] cerebrovascular pathology,10 [LE, 4,C]
brain tumors,11 [LE, 4,C] SCI,12 [LE, 2a,B], myelomeningocele,13 [LE,
2a,B] nerve root compression due to disc disease,14 [LE, 4,C] and
regional spinal anesthesia.15 [LE, 5,D]
4. Clinical symptoms and urodynamic ﬁndings in NLUTD
patients
4.1. Cerebral vascular diseases
The clinical symptoms of NLUTD depend on the levels of le-
sions.16 [LE, 4,C] Because most of the men with CVA are elderly,
some other pathophysiology causing male LUTS, such as BOO,
might confuse the diagnosis and treatment of voiding dysfunction
in patients with CVA.17 [LE, 2b,B]Patients with chronic CVA may have DO causing urinary in-
continence.18 [LE, 2b,B] DU and DHIC might be other problematic
issues in elderly patients with multiple CVA.19 [LE, 2b,B]
Urethral sphincter pseudodyssynergia causing incomplete
bladder emptying and excessive residual urine may develop in
about 10% of patients during the recovery phase (4e10months post
CVA) after stroke.19 [LE, 2b,B]
4.2. PD
PD is a multisystem disorder involving dopaminergic, norad-
renergic, serotoninergic, and cholinergic systems, characterized by
motor and non-motor symptoms.20 [LE, 2a,B]
A previous investigation showed that 40e70% of Parkinsonian
patients have some degree of voiding dysfunction, and nearly 70%
of them have irritative symptoms. DO was the predominant uro-
dynamic ﬁnding.21 [LE, 4,C]
Patients with PD and a hyperactive urethral sphincter might not
be able to adequately relax their urethral sphincter during voli-
tional or reﬂexic micturition, resulting in inadequate detrusor
contractility and increased PVR.22 [LE, 4,C]
4.3. SCI
The incidence of SCI worldwide reported in the literature ranged
from 12.1 per million to 57.8 per million.23 [LE, 2a,B] The most
common etiology of SCI in patients under 60 years old is motor
vehicle crush, whereas in those older than 61 years old, it is fall.24
[LE, 2a,B]
According to the National Health Insurance Research Database
analysis in Taiwan, the frequency of NDO in SCI was around 16.9%
with transient urinary incontinence and 17.5% with permanent
NDO.25 [LE, 3b,B]
Spinal cord lesions can be traumatic, vascular, medical, or
congenital. A high correlation exists between the clinical neuro-
logic ﬁndings and the NLUTD in single-level traumatic spinal cord
lesions, but not in myelomeningocele and combined traumatic
spinal cord lesions.26 [LE, 2a,B] At SCI lesions above T6, patients
may have smooth muscle dyssynergia and AD in addition to DSD.26
[LE, 2a,B]
SCI patients may have LUTS of urgency and UUI. Some patients
with BND and DSD may also experience difﬁcult bladder emptying
and urinary retention.27,28 [LE, 2a,B; LE, 3b,C]
Considering the priority of recovery in SCI patients with para-
plegia or tetraplegia, bladder dysfunction, bowel dysfunction, and
AD are listed in the ﬁrst seven highest priorities that patients
demanded for recovery.29 [LE, 2b,B]
The frequency of incontinence is a strong inﬂuence on HR-QoL.
Patients with CIC by attendant, indwelling transurethral catheter-
ization, and suprapubic catheterization had the worst mental sta-
tus.30 [LE, 2c,B] SCI patients have higher degrees of depression than
a normal population, which is closely related to female gender and
inability to perform self-catheterization.31 [LE, 2b,B]
Many clinicians ignore that NDOmay affect mortality/morbidity.
In addition, SCI patients do not know where or how to get medical
resources.32 [LE, 2b,B] There is an urgent need to increase aware-
ness of patients to understand the urological complications of
NLUTD, and to educate physicians to understand the treatment
strategy of NLUTD.
4.4. MS
MS is a major cause of nontraumatic disability in young adults.
The total estimated prevalence is 83/100,000, most commonly seen
between ages 35 years and 64 years, with a male to female ratio of
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MS, DSD in about 25%, and DU in 19e40% of MS patients. Up to 10%
of patients had bladder dysfunction at initial MS diagnosis.33,34 [LE,
2b,B; LE, 2b,B] In Taiwan, there were 1262 cases of MS during the
period of 2000 through to 2005. The male to female ratio was 0.4.
The average annual incidence rate was 0.79/100,000.35 [LE, 2c,B]
The clinical symptoms of MS patients include urgency (32e
86%), nocturia (25e82%), and UUI (19e80%). They may also have
difﬁcult urination (6e79.5%) and urinary retention (8.3e73.8%),
depending on the involvement of the CNS and the chronicity of
disease.36 [LE, 2a,B]5. Classiﬁcation of NLUTD
A perfect classiﬁcation system is not yet available. Most of the
currently used classiﬁcations of NLUTD are based on the bladder
and urethral dysfunctions. Wein37 and Fall et al38 classiﬁed NLUTD
as failure to store and failure to empty based on detrusor and
urethral dysfunction. [LE, 2a,B; LE, 2a,B]
The ICS also separates the NLUTD as detrusor and urethral
dysfunction in storage and voiding phases. The main problems of
NLUTD are: (1) failure to store due to DO or urethral incompetence;
(2) failure to empty due to DA, BND, or DSD; and (3) combined
failure to store and empty due to DSD or DO and DHIC.1 [LE, 1a,A]
Early diagnosis and treatment is essential, as irreversible
changes may occur. Individual variations exist in the NLUTD caused
by a speciﬁc neurologic lesion. [LE, 5,D]
DO and DSD commonly occur in patients with suprasacral cord
lesions, such as SCI, MS, or transverse myelitis. The presence of DSD
is associated with complete injuries, elevated intravesical pres-
sures, and upper urinary tract complications.26 [LE, 2a,B]6. Classiﬁcation of SCI severity
In the American Spinal Injury Association (ASIA) Impairment
Scale,39 [LE, 1b, A] ASIA-A is deﬁned as a person with no motor or
sensory function preserved in the sacral segments S4eS5. ASIA-B is
essentially identical to Frankel B, but adds the requirement of
preserved sacral S4eS5 sensory function. ASIA-C is if more than half
of the muscles evaluated had a grade of less than 3/5. If not, the
person was assigned to ASIA-D. ASIA-E implies that somebody can
have SCI without having any neurological deﬁcits at least detect-
able on a neurological examination of this type (Table 1).
The ASIA committee also classiﬁed incomplete spinal cord in-
juries into ﬁve types. A central cord syndrome is associated with
greater loss of upper limb function compared to the lower limbs.
The Brown-Sequard syndrome results from a hemisection lesion of
the spinal cord. Anterior cord syndrome occurs when the injury
affects the anterior spinal tracts, including the corticospinal tract.Table 1
The ASIA Impairment Scale.
A¼ Complete: Nomotor or sensory function is preserved in the sacral segments
S4eS5.
B ¼ Incomplete: Sensory but not motor function is preserved below the
neurological level and includes the sacral segments S4eS5.
C ¼ Incomplete: Motor function is preserved below the neurological level, and
more than half of the key muscles below the neurological level have a
muscle grade <3.
D ¼ Incomplete: Motor function is preserved below the neurological level, and
at least half of the key muscles below the neurological level have a muscle
grade of 3.
E ¼ Normal: Motor and sensory functions are normal.
ASIA ¼ American Spinal Injury Association.Conus medullaris and cauda equina syndromes occur with damage
to the conus or spinal roots of the cord.
7. Diagnosis of NLUTD
Diagnosis of NLUTD should be based on neurological lesions and
somatic and visceral dysfunctions. Medical comorbidity may alter
the LUTS.12 [LE, 2a,B]
8. Urological surveillance
The assessments of patients with NLUTD include: urinalysis,
urine culture, renal function test, GFR, intravenous pyelography,
renal ultrasound, renal scan, voiding cystourethrography, cystos-
copy, and urodynamics at physicians’ discretions.
Video urodynamics is the gold standard in patients with NLUTD
to detect bladder and urethral dysfunction, as well as morpholog-
ical pathology in the lower and upper urinary tracts.40e42 [LE, 2a,B;
LE, 2a,B; LE, 2a,B] Should this not be available, then a ﬁlling cyst-
ometry continuing into a pressure ﬂow study should be performed.
9. Selecting high risk patients
It is important to screen the patients at high risk, including
patients with complete neurological lesion, cervical spinal cord
paraplegics, a prolonged indwelling catheter, high detrusor leak
point pressure (DLPP), presence of DSD and AD, large PVR, presence
of VUR, urolithiasis, and recurrent UTI. Detrusor leak point pressure
is an important parameter, especially in patients with endangered
upper urinary tracts.43 [LE, 2a,B]When the DLPP is>40 cmH2O, the
upper tract is endangered.40,43 [LE, 2a,B; LE, 2a,B]
10. Non-surgical treatment of NLUTD
The main goals of treatment of NLUTD are: (1) correction of
urinary tract complications including hydronephrosis, VUR, UTI,
and contracted bladder; (2) lowering intravesical pressure, con-
trolling or alleviating symptoms (including incontinence and
difﬁcult urination)40,43; [LE, 2a,B; LE, 2a,B] (3) improving QoL, to
treat urinary incontinence and difﬁcult urination, to improve
bladder emptying, to avoid indwelling catheter and UTI44,45; [LE,
2a,B; LE, 2a,B] and (4) further considering the patient’s disability,
the cost effectiveness, the technical intricacy, and the possible
complications. It is important that individual strategy for each
NLUTD patient is mandatory.
10.1. Conservative management of NLUTD
Conservative management is the mainstay of urological treat-
ment for NLUTD if possible. Behavioral modiﬁcation should be the
ﬁrst management. CIC either by themselves or by a care-giver is
recommended in patients who cannot have a balanced bladder
(deﬁned as adequate bladder emptying with a low intravesical
pressure and low PVR). Patients can be instructed to void by
abdominal stimulation (triggered reﬂex voiding), Crede maneuver,
or abdominal straining (Valsalva). Spontaneous voiding with and
without triggered voiding and/or bladder expression has proven to
be less safe, except in well-deﬁned patients with regular urological
follow-up.46,47 [LE, 2a,B; LE, 2b,B]
In patients with poor hand function and urinary incontinence,
an external appliance is feasible to collect urine. Long-term
indwelling catheters should be avoided unless for patients with
tetraplegia and who are bed-bound, in whom suprapubic cys-
tostomy or an indwelling urethral Foley catheter may be an alter-
native choice.48e50 [LE, 2a,B; LE, 3b,C; LE, 2a,B]
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Intermittent catheterization (IC) is the standard treatment for
patients who are unable to empty the bladder.51,52 [LE, 2b,B; LE,
2a,B] Patients should be well instructed on the technique and risks
of IC. Aseptic or CIC is the recommended method.
Indwelling transurethral and suprapubic catheterization should
be used only in exceptional circumstances, under close control, and
the catheter should be changed frequently. Silicone catheters are
preferred and should be changed every 2e4 weeks; (coated) latex
catheters need to be changed every 1e2 weeks.48 [LE, 2b,B]10.3. Drug treatment of NLUTD
NDO can be treated effectively by anticholinergic substances
(such as oxybutynin, tolterodine, trospium, propiverine, sol-
ifenacin, etc.).53e56 [LE, 1b,A; LE, 1b,A; LE, 1b,A; LE, 4,C] Long-term
efﬁcacy and safety of antimuscarinic therapy for NDO is well
documented. A combination of antimuscarinic agents can be used
in patients who were insufﬁciently treated with a single anti-
muscarinic agent, and is often considered to maximize outcomes
for NDO.57 [LE, 3b,C] In a highly selected group of patients with
NDO and poor bladder compliance, combination medical therapy
with two or three drugs improved compliance, decreased bladder
pressures at capacity, and improved clinical outcomes.58 [LE, 4,D]
There is no well-designed study available on drugs for
improving detrusor contractility. Using oral bethanechol can in-
crease intravesical tone and facilitate bladder emptying by
abdominal straining in patients who responded positively to the
electromotive intravesical bethanechol testing.59 [LE, 4,C] However,
some patients may beneﬁt from bethanechol. [LE, 5,D]
Alpha-blockers (such as alfuzosin, terazosin, doxazosin, tamsu-
losin, or silodosin) and skeletal muscle relaxants (such as baclofen
or diazepam) have been used partly successfully in decreasing
bladder outlet resistance.60e62 [LE, 4,C; LE, 2a,B; LE, 3b,B]
Because patients with NLUTD may suffer from both storage and
empty LUTS, a combination of medication to improve bladder
storage and facilitate bladder emptying can be used.63 [LE, 2a,B] For
most patients, ﬂexible dosing with an anticholinergic agent, with
CIC when indicated, has been shown to reduce the risks of uro-
logical complications, improve levels of continence, and enhance
patient QoL in both children and adults.64 [LE, 2a,B]10.4. Botulinum toxin bladder and urethral injections
The treatment strategy for NLUTD should be a less invasive and
reversible procedure, such as neurotoxin injection into detrusor or
urethral sphincter for bladder control and emptying. Botulinum
toxin-A (BoNT-A, Botox) intradetrusor injection has been demon-
strated to be effective in the restoration of urinary continence and
remains durable from 3 months to 9 months.65e67 [LE, 3b,B; LE,
1b,A; LE, 3b,B] Detrusor BoNT-A injection increases bladder ca-
pacity and decreases intravesical pressure. Doses of 200 U and
300 U Botox produce the same therapeutic effects on NDO, and
200 U is approved by the Food and Drug Administration.68 [LE,
1b,A] Repeat BoNT-A detrusor injections seem to be as effective as
the ﬁrst injection.69 [LE, 3b,B]
Detrusor BoNT-A injection is also effective in treating children
with myelomeningocele with DO and incontinence.70,71 [LE, 3b,B;
LE, 3b,B] BoNT-A signiﬁcantly reduced the maximum pressure of
uninhibited detrusor contractions more than resiniferatoxin at all
follow-up time points.72 [LE, 2b,B]
Clinically, detrusor BoNT-A injection usually induces impaired
detrusor contractility, large PVR or urinary retention in NDO, about70% of patients require periodic CIC, and subsequent UTI could
become a de novo problem.73 [LE, 2b,B]
In patients with PD and refractory DO, intradetrusor injection of
100 U BoNT-A also induced clinical and urodynamic improvement
in overactive bladders that lasts for 6 months.74 [LE, 4,C]
Detrusor 200 U BoNT-A injection is the recommended dose for
patients with NDO to decrease intravesical pressure and achieve
continence. Under some conditions, a starting dose of 100 U
detrusor injection might be feasible in case that the patient wants
to preserve spontaneous voiding function or CIC/CISC is not
acceptable. However, if the patient is not satisﬁed with the thera-
peutic effect of 100 U, 200 U detrusor BoNT-A should be used in the
following treatment.
Urethral BoNT-A injection can reduce urethral resistance in
patients with DSD or DA.75,76 [LE, 3b, B; LE, 3b,B;] Early return of
detrusor contractility seems possible in patients with DU and
urethral sphincter pseudodyssynergia due to CVA or PD.77 [LE, 3b,C]
10.5. Urethral or detrusor BoNT-A injections for DSD?
Patients with DSD usually have both storage and empty symp-
toms. Patients with DSD may prefer to be dry and perform CIC by
themselves, or prefer spontaneous voiding without instituting
CIC.78 [LE, 3b,C] Therefore, management of voiding dysfunction and
incontinence in patients with SCI and DSD is a challenge to physi-
cians and should be considered an art-of-the-medicine.
About 95% of patients with suprasacral lesions demonstrated DO
with or without DSD.79 [LE, 2a,B] The hand dexterity, abdominal
muscle power, bladder sensation, and the degree of urethral
sphincter dyssynergia might affect the voiding efﬁciency and LUTD.
Urethral BoNT-A injection can reduce urethral resistance.65,75 [LE,
3b,B; LE, 3b,B] Combined detrusor and urethral sphincter BoNT-A
injections may achieve continence control and volitional void-
ing.80 [LE, 3b,B]
Treatment of NDO and DSDmight be different between genders.
Physicians should consider the patient’s expectation and ability of
bladder management when planning BoNT-A injection into
detrusor or urethral sphincter in treatment of NLUTD.81 [LE, 3b,B]
There are several important issues that physicians should know
prior to when they perform BoNT-A injection to patients with
NLUTD: (1) behavioral modiﬁcation should be the ﬁrst manage-
ment; (2) BoNT-A injection should be given to patients in whom
antimuscarinics failed or produced intolerable adverse events; (3)
CIC is necessary for most patients to respond to BoNTA; (4) moni-
toring PVR and subsequent UTI is necessary; (5) monitoring upper
urinary tracts is important; (6) repeated BoNT-A injections are
necessary to maintain the desired therapeutic effect; and (7) pa-
tients with urethral stricture, unwillingness to perform CIC, and in
whom BoNT-A is contraindicated should not be tried. [LE, 5,D]
10.6. Renal function preservation
The renal function is also an important issue in management of
NLUTD, especially in chronic SCI patients. Patients with DSD, low
compliant bladder, and high intravesical pressure at end-bladder
ﬁlling may be at high risk of renal failure. The incidence of
chronic renal disease in paraplegia and neural tube defects is higher
than in a normal population.82 [LE, 2a,B]
Low bladder compliance was statistically associated with VUR,
radiographic upper urinary tract abnormality, pyelonephritis, and
upper urinary tract stones. CIC is the superior method for preser-
ving bladder compliance and preventing the upper urinary tract
complications associated with low compliance.83 [LE, 4,C]
Patients with DSD who currently have an indwelling catheter,
who are performing CIC or who have spontaneous voiding should
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ciency. Oral antimuscarinic agents or intravesical BoNT-A injections
might provide a low-pressure bladder and preserve renal function
in long-term management of NLUTD. [LE, 5,D]10.7. AD dysreﬂexia and UTI in SCI
AD is a potentially life-threatening condition. AD occurs most
often in individuals with SCI above the T6 level.84 [LE, 4,C] Patients
with chronic SCI may develop AD during bladder overdistension,
stool impaction, or UTI.85 [LE, 2a,B] The incidence of AD in patients
with SCI above T6 ranged from 19% to 70%. Patients with DSD had a
higher incidence of AD.
Alpha-blockers or detrusor BoNT-A injections have been proven
to be able to alleviate the occurrence of AD. However, some SCI
patients may develop exacerbated AD after BoNT-A injection.77 [LE,
3b,B]11. Surgical management of NVD
For patients without therapeutic responses to medical treat-
ment or intravesical BoNT-A injection, surgical intervention is
mandatory to treat urological complications and preserve renal
function.
Transurethral external sphincterotomy provides a signiﬁcant
reduction of voiding pressure and AD in male SCI patients.86 [LE,
3b,B]
Transurethral incision of BN (TUI-BN) can also reduce AD and
facilitate spontaneous voiding in incomplete cervical SCI patients.87
[LE, 3b,B] TUI-BN is effective in restoring spontaneous voiding,
increasing Qmax, and decreasing PVR in high-level SCI patients.
TUI-BN also leads to an improvement in reducing bladder outlet
resistance, a reduction in occurrence of AD episodes, and an
improvement in HR-QoL.88 [LE, 3b,B]
Bladder augmentation, either by a segment of intestine, or auto-
augmentation using myomectomy, can reach a large capacity, low
intravesical pressure, and non-reﬂux condition.89,90 [LE, 2a,B; LE,
3b,C] However, long-term complications such as stone formation,
loose stool, metabolic acidosis, and chronic UTI remain problems to
be solved.91 [LE, 3b,B]
Other surgical treatments for NLUTD to increase bladder ca-
pacity and improve storage function include: urethral and
bladder neck procedures, urethral sling, artiﬁcial urinary
sphincter,92 [LE, 2a,B] functional sphincter augmentation, bladder
neck and urethra reconstruction (Young-Dees-Leadbetter proce-
dure),93 [LE, 3b,B] detrusor myectomy (auto-augmentation),
denervation, deafferentiation, neurostimulation, neuro-
modulation, sacral rhizotomy and sacral anterior root stimulation
, bladder covering by striated muscle, or urinary diversion.89 [LE,
2a,B]11.1. Treatment of VUR
Ureteral reimplantation has an immediate and long-lasting
result in over 90% of patients.94,95 [LE, 3b,B; LE, 3b,B] Subtrigonal
injections of bulking agents may be tried ﬁrst in selected patients
with NLUTD and VUR.96 [LE, 3b,B]
Ureteral reimplantation alone or combined ureteral reimplan-
tation with bladder augmentation in patients with contracted
bladder are effective procedures in patients who fail the initial in-
jection procedure.97 [LE, 3b,B] In the treatment of VUR, physicians
should consider lowering intravesical pressure at the same time.98
[LE, 3b,C]12. QoL issues
The QoL issue is also important in the treatment strategy for
NLUTD. Patients’ will of management modality, their hand function
and capability of self-care, social economic support, and family
support for patients with NLUTD should be taken into consider-
ation in the management of NLUTD.
When performing BoNT-A injections for patients with DSD,
injecting into the detrusor or urethra should be carefully evaluated
prior to treatment. Patients with DSD and treated with detrusor
BoNT-A had a greater HR-QoL improvement than those treated
with urethral injection.99 [LE, 2b,B]13. Rational treatment strategy for NLUTD
Bladder and urethral dysfunction changes with time in patients
with NLUTD. In treating patients with NLUTD, patients should be
regularly followed up for their lower urinary tract dysfunction and
any urological complication should be adequately treated.
Avoiding a chronic indwelling catheter can reduce the incidence
of developing a low compliant bladder.
Long-term antimuscarinic therapy can decrease urinary incon-
tinence and lower intravesical pressure.
Intravesical injection of BoNT-A provides an alternative treat-
ment for refractory DO or low compliant bladder and can replace
the need for bladder augmentation.
When surgical intervention is necessary, we should consider the
least invasive type of surgery and reversible procedure ﬁrst and
avoid any unnecessary surgery of the lower urinary tract.14. Future new technologies
Many novel therapeutic trials have emerged in recent decades to
treat SCI and NLUTD. Keeping the bladder and urethra in a good
condition without interference of the neuromuscular continuity
provides patients with NLUTD a chance for future new technolo-
gies. The most important thing is to never give up on improving the
QoL in patients with NLUTD.15. Guidelines for follow-up
All patients should receive life-long annual surveillance to
prevent development of urological complications and undesired
LUTS.100 [LE, 2a,B]
The long-term follow-up procedures include: physical exami-
nation, blood chemistry, urinalysis, renal ultrasound, bladder ul-
trasound, PVR measurement, cystoscopy, renal scan, and
urodynamic study. [see Assessment]
More frequent examinations are needed in patients with a high
risk or if the neurological pathology or the NLUTD status demand
this.Conﬂicts of interest
The authors declare that they have no ﬁnancial or non-ﬁnancial
conﬂicts of interest related to the subject matter or materials dis-
cussed in the manuscript.Source of Funding
None.
H.-C. Kuo et al. / Urological Science 25 (2014) 35e4140References
1. Abrams P, Cardozo L, Fall M, Grifﬁths D, Rosier P, Ulmsten U, et al. The
standardisation of terminology of lower urinary tract function: report from
the Standardisation Sub-committee of the International Continence Society.
Neurourol Urodyn 2002;21:167e78.
2. Abrams P, Andersson KE, Birder L, Brubaker L, Cardozo L, Chapple C, et al.
Fourth International Consultation on Incontinence Recommendations of the
International Scientiﬁc Committee: evaluation and treatment of urinary in-
continence, pelvic organ prolapse, and fecal incontinence. Neurourol Urodyn
2010;29:213e40.
3. Ku JH. The management of neurogenic bladder and quality of life in spinal
cord injury. BJU Int 2006;98:739e45.
4. Kuo HC. Quality of life after active urological management of chronic spinal
cord injury in eastern Taiwan. Eur Urol 1998;34:37e46.
5. Bradley WE. Diagnosis of urinary bladder dysfunction in diabetes mellitus.
Ann Intern Med 1980;92:323e6.
6. Seski JC, Diokno AC. Bladder dysfunction after radical abdominal hysterec-
tomy. Am J Obstet Gynecol 1977;128:643e51.
7. Fowler CJ, van Kerrebroeck PE, Nordenbo A, Van Poppel H. Treatment of lower
urinary tract dysfunction in patients with multiple sclerosis. Committee of the
European Study Group of SUDIMS (Sexual and Urological Disorders in Mul-
tiple Sclerosis). J Neurol Neurosurg Psychiatry 1992;55:986e9.
8. Olsen CG, Clasen ME. Senile dementia of the Binswanger’s type. Am Fam
Physician 1998;58:2068e74.
9. Salinas JM, Berger Y, De La Rocha RE, Blaivas JG. Urological evaluation in the
Shy Drager syndrome. J Urol 1986;135:741e3.
10. Barer DH. Continence after stroke, useful predictor of goal of therapy? Age
Aging 1989;18:183e91.
11. Andrew J, Nathan PW. Lesions of the anterior frontal lobes and disturbances of
micturition and defecation. Brain 1964;87:233e62.
12. Burns AS, Rivas DA, Ditunno JF. The management of neurogenic bladder and
sexual dysfunction after spinal cord injury. Spine (Phila Pa 1976) 2001;26(24
Suppl.):S129e36.
13. van Gool JD, Dik P, de Jong TP. Bladder-sphincter dysfunction in myelome-
ningocele. Eur J Pediatr 2001;160:414e20.
14. Rosomoff HL, Johnston JD, Gallo AE, Ludmer M, Givens FT, Carney FT, et al.
Cystometry in the evaluation of nerve root compression in the lumbar spine.
Surg Gynecol Obstet 1963;117:263e70.
15. Mardirosoff C, Dumont L. Bowel and bladder dysfunction after spinal bupi-
vacaine. Anesthesiology 2001;95:1306.
16. Kaplan SA, Chancellor MB, Blaivas JG. Bladder and sphincter behavior in pa-
tients with spinal cord lesions. J Urol 1991;146:113e7.
17. Borrie MJ, Campbell AJ, Caradoc-Davies TH, Spears GF. Urinary incontinence
after stroke: a prospective study. Age Ageing 1986;15:177e81.
18. Taub NA, Wolfe CD, Richardson E, Burney PG. Predicting the disability of ﬁrst-
time stroke sufferers at 1 year. 12-Month follow-up of a population-based
cohort in southeast England. Stroke 1994;25:352e7.
19. Blaivas JG. The neurophysiology of micturition: a clinical study of 550 pa-
tients. J Urol 1982;127:958e63.
20. Awad RA. Neurogenic bowel dysfunction in patients with spinal cord injury,
myelomeningocele, multiple sclerosis and Parkinson’zs disease. World J Gas-
troenterol 2011;17:5035e48.
21. Pavlakis AJ, Siroky MB, Goldstein I, Krane RJ. Neurourologic ﬁndings in Par-
kinson’s disease. J Urol 1983;129:80e3.
22. Wang SN, Kuo HC. Videourodynamic ﬁndings in Parkinson’s disease. JTUA
2007;18:23e6.
23. van den Berg ME, Castellote JM, Mahillo-Fernandez I, de Pedro-Cuesta J.
Incidence of spinal cord injury worldwide: a systematic review. Neuro-
epidemiology 2010;34:184e92.
24. Jackson AB, Dijkers M, Devivo MJ, Poczatek RB. A demographic proﬁle of new
traumatic spinal cord injuries: change and stability over 30 years. Arch Phys
Med Rehabil 2004;85:1740e8.
25. Lai EC, Kao Yang YH, Kuo HC. Complication rate of neurogenic lower urinary
tract dysfunction after spinal cord injury in Taiwan. Int Urol Nephrol 2013 Dec
18 [Epub ahead of print]. http://dx.doi.org/10.1007/s11255-013-0625-6.
26. Weld KJ, Dmochowski RR. Association of level of injury and bladder
behavior in patients with post-traumatic spinal cord injury. Urology
2000;55:490e4.
27. Weld KJ, Graney MJ, Dmochowski RR. Difference in bladder compliance with
time and associations of bladder management with compliance in spinal cord
injured patients. J Urol 2000;163:1228e33.
28. Al-Ali M, Haddad L. A 10 year review of the endoscopic treatment of 125
spinal cord injured patients with vesical outlet obstruction: does bladder neck
dyssynergia exist? Paraplegia 1996;34:34e8.
29. Anderson KD. Targeting recovery: priorities of the spinal cord-injured pop-
ulation. J Neurotrauma 2004;21:1371e83.
30. Liu CW, Attar KH, Gall A, Shah J, Craggs M. The relationship between bladder
management and health-related quality of life in patients with spinal cord
injury in the UK. Spinal Cord 2010;48:319e24.
31. Oh SJ, Shin HI, Paik NJ, Yoo T, Ku JH. Depressive symptoms of patients using
clean intermittent catheterization for neurogenic bladder secondary to spinal
cord injury. Spinal Cord 2006;44:757e62.32. Thietje R, Giese R, Pouw M, Kaphengst C, Hosman A, Kienast B, et al. How does
knowledge about spinal cord injury-related complications develop in subjects
with spinal cord injury? A descriptive analysis in 214 patients. Spinal Cord
2011;49:43e8.
33. Giannantoni A, Scivoletto G, Di Stasi SM, Grasso MG, Vespasiani G,
Castellano V. Urological dysfunctions and upper urinary tract involvement in
multiple sclerosis patients. Neurourol Urodyn 1998;17:89e98.
34. Koldewijn EL, Hommes OR, Lemmens WA, Debruyne FM, van Kerrebroeck PE.
Relationship between lower urinary tract abnormalities and disease-related
parameters in multiple sclerosis. J Urol 1995;154:169e73.
35. Lai CH, Tseng HF. Population-based epidemiological study of neurological
diseases in Taiwan: I. Creutzfeldt-Jakob disease and multiple sclerosis. Neu-
roepidemiology 2009;33:247e53.
36. de Sèze M, Rufﬁon A, Denys P, Joseph PA, Perrouin-Verbe B, GENULF. The
neurogenic bladder in multiple sclerosis: review of the literature and proposal
of management guidelines. Mult Scler 2007;13:915e28.
37. Wein AJ. Pathophysiology and categorization of voiding dysfunction. In:
Walsh PC, Retik AB, Vaughan Jr ED, editors. Campbell’s Urology. 4th ed. Phil-
adelphia: WB Saunders; 1998. pp. 917e26.
38. Fall M, Ohlsson BL, Carlsson CA. The neurogenic overactive bladder. Classiﬁ-
cation based on urodynamics. Br J Urol 1989;64:368e73.
39. Marino RJ, Barros T, Biering-Sorensen F, Burns SP, Donovan WH, Graves DE,
et al. International standards for neurological classiﬁcation of spinal cord
injury. J Spinal Cord Med 2003;26(Suppl. 1):S50e6.
40. Stöhrer M, Goepel M, Kondo A, Kramer G, Madersbacher H, Millard R, et al.
The standardization of terminology in neurogenic lower urinary tract
dysfunction with suggestions for diagnostic procedures. Neurourol Urodyn
1999;18:139e58.
41. Rivas DA, Chancellor MB. Neurogenic vesical dysfunction. Urol Clin North Am
1995;22:579e91.
42. Madersbacher HG. Neurogenic bladder dysfunction. Curr Opin Urol 1999;9:
303e7.
43. McGuire EJ, Cespedes RD, O’Connell HE. Leak-point pressures. Urol Clin North
Am 1996;23:253e62.
44. Hackler RH. A 25-year prospective mortality study in the spinal cord injured
patient: comparison with the long-term living paraplegic. J Urol 1977;117:
486e8.
45. Perkash I, Giroux J. Prevention, treatment, and management of urinary tract
infections in neuropathic bladders. J Am Paraplegia Soc 1985;8:15e7.
46. Wyndaele JJ, Madersbacher H, Kovindha A. Conservative treatment of the
neuropathic bladder in spinal cord injured patients. Spinal Cord 2001;39:294e
300.
47. Barbalias GA, Klauber GT, Blaivas JG. Critical evaluation of the Crede ma-
neuver: a urodynamic study of 207 patients. J Urol 1983;130:720e3.
48. Weld KJ, Dmochowski RR. Effect of bladder management on urological com-
plications in spinal cord injured patients. J Urol 2000;163:768e72.
49. Larsen LD, Chamberlin DA, Khonsari F, Ahlering TE. Retrospective analysis of
urologic complications in male patients with spinal cord injury managed with
and without indwelling urinary catheters. Urology 1997;50:418e22.
50. Weld KJ, Wall BM, Mangold TA, Steere EL, Dmochowski RR. Inﬂuences on
renal function in chronic spinal cord injured patients. J Urol 2000;164:
1490e3.
51. Guttmann L, Frankel H. The value of intermittent catheterisation in the early
management of traumatic paraplegia and tetraplegia. Paraplegia 1966;4:63e84.
52. Lapides J, Diokno AC, Silber SJ, Lowe BS. Clean, intermittent self-
catheterization in the treatment of urinary tract disease. J Urol 1972;107:
458e61.
53. Madersbacher H, Stöhrer M, Richter R, Burgdörfer H, Hachen HJ, Mürtz G.
Trospium chloride versus oxybutynin: a randomized, double-blind, multi-
centre trial in the treatment of detrusor hyperreﬂexia. Br J Urol 1995;75:
452e6.
54. Goessl C, Sauter T, Michael T, Berge B, Staehler M, Miller K. Efﬁcacy and
tolerability of tolterodine in children with detrusor hyperreﬂexia. Urology
2000;55:414e8.
55. Thuroff JW, Bunke B, Ebner A, Faber P, de Geeter P, Hannappel J, et al. Ran-
domized, double-blind, multicenter trial on treatment of frequency, urgency
and incontinence related to detrusor hyperactivity: oxybutynin versus
propantheline versus placebo. J Urol 1991;145:813e6.
56. Krebs J, Pannek J. Effects of solifenacin in patients with neurogenic detrusor
overactivity as a result of spinal cord lesion. Spinal Cord 2013;51:306e9.
57. Amend B, Hennenlotter J, Schäfer T, Horstmann M, Stenzl A, Sievert KD.
Effective treatment of neurogenic detrusor dysfunction by combined high-
dosed antimuscarinics without increased side-effects. Eur Urol 2008;53:
1021e8.
58. Cameron AP, Clemens JQ, Latini JM, McGuire EJ. Combination drug therapy
improves compliance of the neurogenic bladder. J Urol 2009;182:1062e7.
59. Riedl CR, Stephen RL, Daha LK, Knoll M, Plas E, Pﬂuger H. Electromotive
administration of intravesical bethanechol and the clinical impact on a con-
tractile detrusor management: introduction of a new test. J Urol 2000;164:
2108e11.
60. Perkash I. Efﬁcacy and safety of terazosin to improve voiding in spinal cord
injury patients. J Spinal Cord Med 1995;18:236e9.
61. Sullivan J, Abrams P. Alpha-adrenoceptor antagonists in neurogenic lower
urinary tract dysfunction. Urology 1999;53(3 Suppl. 3a):21e7.
H.-C. Kuo et al. / Urological Science 25 (2014) 35e41 4162. Schulte-Baukloh H, Michael T, Miller K, Knispel HH. Alfuzosin in the treatment
of high leak-point pressure in children with neurogenic bladder. BJU Int
2002;90:716e20.
63. Ruggieri MR, Braverman AS, Pontari MA. Combined use of alpha-adrenergic
and mascarinic antagonists for the treatment of voiding dysfunction. J Urol
2005;174:1743e8.
64. Chancellor MB, Anderson RU, Boone TB. Pharmacotherapy for neurogenic
detrusor overactivity. Am J Phys Med Rehabil 2006;85:536e45.
65. Schurch B, Stohrer M, Kramer G, Schmid DM, Gaul G, Hauri D. Botulinum-A
toxin for treating detrusor hyperreﬂexia in spinal cord injured patients: a new
alternative to anticholinergic drugs? Preliminary results. J Urol 2000;164:
692e7.
66. Ehren I, Volz D, Farrelly E, Berglund L, Brundin L, Hultling C, et al. Efﬁcacy and
impact of botulinum toxin A on quality of life in patients with neurogenic
detrusor overactivity: a randomized, placebo-controlled, double-blind study.
Scand J Urol Nephrol 2007;41:335e40.
67. Patki PS, Hamid R, Arumugam K, Shah PJ, Craggs M. Botulinum toxin-type A in
the treatment of drug-resistant neurogenic detrusor overactivity secondary to
traumatic spinal cord injury. BJU Int 2006;98:77e82.
68. Cruz F, Herschorn S, Aliotta P, Brin M, Thompson C, Lam W, et al. Efﬁcacy and
safety of onabotulinumtoxinA in patients with urinary incontinence due to
neurogenic detrusor overactivity: a randomized, double-blind, placebo-
controlled trial. Eur Urol 2011;60:742e50.
69. Akbar M, Abel R, Seyler TM, Gerner HJ, Mohring K. Repeated botulinum-A
toxin injections in the treatment of myelodysplastic children and patients
with spinal cord injuries with neurogenic bladder dysfunction. BJU Int
2007;100:639e45.
70. Riccabona M, Koen M, Schindler M, Goedele B, Pycha A, Lusuardi L, et al.
Botulinum-A toxin injection into the detrusor: a safe alternative in the
treatment of children with myelomeningocele with detrusor hyperreﬂexia.
J Urol 2004;171:845e8.
71. Kajbafzadeh AM, Moosavi S, Tajik P, Arshadi H, Payabvash S, Salmasi AH, et al.
Intravesical injection of botulinum toxin type A: management of neuropathic
bladder and bowel dysfunction in children with myelomeningocele. Urology
2006;68:1091e7.
72. Gianantoni A, Mearini E, Di Stasi SM, Costantini E, Zucchi A, Mearini L, et al.
New therapeutic options for refractory neurogenic detrusor overactivity.
Minerva Urol Nefrol 2004;56:79e87.
73. Reitz A, Stohrer M, Kramer G, Del Popolo G, Chartier-Kastler E, Pannek J, et al.
European experience of 200 cases treated with botulinum-A toxin injections
into the detrusor muscle for urinary incontinence due to neurogenic detrusor
overactivity. Eur Urol 2004;45:510e5.
74. Giannantoni A, Conte A, Proietti S, Giovannozzi S, Rossi A, Fabbrini G, et al.
Botulinum toxin type A in patients with Parkinson’s disease and refractory
overactive bladder. J Urol 2011;186:960e4.
75. Kuo HC. Botulinum A toxin urethral injection for the treatment of lower
urinary tract dysfunction. J Urol 2003;170:1908e12.
76. Schurch B. Neurogenic voiding disorders. Current status of diagnosis and
therapy. Schweiz Med Wochenschr 2000;130:1618e26.
77. Chen SF, Kuo HC. Improvement in autonomic dysreﬂexia after detrusor
onabotulinumtoxinA injections in patients with chronic spinal cord injuries.
Tzu Chi Med J 2012;24:201e4.
78. Kuo HC. Therapeutic effects of suburothelial injection of botulinum a toxin for
neurogenic detrusor overactivity due to chronic cerebrovascular accident and
spinal cord lesions. Urology 2006;67:232e6.
79. Weld KJ, Graney MJ, Dmochowski RR. Clinical signiﬁcance of detrusor
sphincter dyssynergia type in patients with post-traumatic spinal cord injury.
Urology 2000;56:565e8.80. Schulte-Baukloh H, Weiss C, Stolze T, Herholz J, Stürzebecher B, Miller K, et al.
Botulinum-A toxin detrusor and sphincter injection in treatment of overactive
bladder syndrome: objective outcome and patient satisfaction. Eur Urol
2005;48:984e90.
81. Kuo HC. Therapeutic satisfaction and dissatisfaction in patients with spinal
cord lesion and detrusor sphincter dyssynergia who received detrusor botu-
linum toxin A injection. Urology 2008;72:1056e60.
82. Lawrenson R, Wyndaele JJ, Vlachonikolis I, Farmer C, Glickman S. Renal failure
in patients with neurogenic lower urinary tract dysfunction. Neuro-
epidemiology 2001;20:138e43.
83. Yiangou Y, Facer P, Ford A, Brady C, Wiseman O, Fowler CJ, et al. Capsaicin
receptor VR1 and ATP-gated ion channel P2X3 in human urinary bladder. BJU
Int 2001;87:774e9.
84. Valles M, Benito J, Portell E, Vidal J. Cerebral hemorrhage due to autonomic
dysreﬂexia in a spinal cord injury patient. Spinal Cord 2005;43:738e40.
85. Karlsson AK. Autonomic dysreﬂexia. Spinal Cord 1999;37:383e91.
86. Perkash I. Transurethral sphincterotomy provides signiﬁcant relief in auto-
nomic dysreﬂexia in spinal cord injured male patients: long-term followup
results. J Urol 2007;177:1026e9.
87. Perkash I. Contact laser sphincterotomy: further experience and longer
follow-up. Spinal Cord 1996;34:227e33.
88. Ke QS, Kuo HC. Transurethral incision of the bladder neck to treat bladder
neck dysfunction and voiding dysfunction in patients with high-level spinal
cord injuries. Neurourol Urodyn 2010;29:748e52.
89. Castro-Diaz D, Barrett D, Grise P, Perkash I, Stöhrer M, Stone A, et al. Surgery
for the neuropathic patient. In: Abrams P, Khoury S, Wein A, editors. Incon-
tinence. 2nd ed. Plymouth: Health Publication Ltd; 2002. pp. 865e91.
90. Stöhrer M, Kramer A, Goepel M, Lochner-Ernst D, Kruse D, Rübben H. Bladder
auto-augmentationean alternative for enterocystoplasty: preliminary results.
Neurourol Urodyn 1995;14:11e23.
91. Blaivas JG, Weiss JD, Desai P, Flisser AJ, Stember DS, Stahl PJ. Long-term fol-
lowup of augmentation enterocystoplasty and continent diversion in patients
with benign disease. J Urol 2005;173:1631e4.
92. Light JK, Scott FB. Use of the artiﬁcial urinary sphincter in spinal cord injury
patients. J Urol 1983;130:1127e9.
93. Donnahoo KK, Rink RC, Cain MP, Casale AJ. The Young-Dees-Leadbetter
bladder neck repair for neurogenic incontinence. J Urol 1999;161:1946e9.
94. Engel JD, Palmer LS, Cheng EY, Kaplan WE. Surgical versus endoscopic
correction of vesicoureteral reﬂux in children with neurogenic bladder
dysfunction. J Urol 1997;157:2291e4.
95. Granata C, Buffa P, Di Rovasenda E, Mattioli G, Scarsi PL, Podesta E, et al.
Treatment of vesico-ureteric reﬂux in children with neuropathic bladder: a
comparison of surgical and endoscopic correction. J Pediatr Surg 1999;34:
1836e8.
96. Haferkamp A, Mohring K, Staehler G, Gerner HJ, Dorsam J. Long-term efﬁcacy
of subureteral collagen injection for endoscopic treatment of vesicoureteral
reﬂux in neurogenic bladder cases. J Urol 2000;163:274e7.
97. Simforoosh N, Tabibi A, Basiri A, Noorbala MH, Danesh AD, Ijadi A. Is ureteral
reimplantation necessary during augmentation cystoplasty in patients with
neurogenic bladder and vesicoureteral reﬂux? J Urol 2002;168:1439e41.
98. Lopez Pereira P, Martinez Urrutia MJ, Lobato Romera R, Jaureguizar E. Should
we treat vesicoureteral reﬂux in patients who simultaneously undergo
bladder augmentation for neuropathic bladder? J Urol 2001;165:2259e61.
99. Kuo HC. Therapeutic outcome and quality of life between urethral and
detrusor botulinum toxin treatment for patients with spinal cord lesions and
detrusor sphincter dyssynergia. Int J Clin Pract 2013;67:1044e9.
100. Nijman RJ. Neurogenic and non-neurogenic bladder dysfunction. Curr Opin
Urol 2001;11:577e83.
